𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The homocysteine pathway: A new target for Alzheimer disease treatment?

✍ Scribed by José I. Lao; Katrin Beyer; Aurelio Ariza

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
141 KB
Volume
62
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

β-secretase as a target for the treatmen
β-secretase as a target for the treatment of Alzheimer's disease
✍ Martin Citron 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

## Abstract Finding inhibitors of the first step of the amyloid cascade, Aβ~42~ generation, is a major goal of Alzheimer's disease drug development. Two target protease activities, β‐and γ‐secretase, were detected more than 10 years ago but progress in this area has been slow because the enzymes we

Radiotracers for a multi-target approach
Radiotracers for a multi-target approach to the diagnosis of Alzheimer's disease
✍ Jogeshwar Mukherjee; Elizabeth Head; Rama Pichika; Balasubramaniam Easwaramoorth 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB

## Abstract Development of __β__‐amyloid plaques and neurofibrillary tangles is the hallmark of Alzheimer's disease (AD) and progressively affects the overall functioning of the brain. Noninvasive imaging methods aiding early diagnosis will significantly improve benefits provided by treatments and

Xanomeline: A selective muscarinic agoni
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected